1099474-22-2Relevant academic research and scientific papers
NMDA (N-METHYL-D-ASPARTATE) ANTAGONISTS
-
Page/Page column 31, (2010/02/14)
The present invention is new excitatory amino acid antagonists (herein referred to as compounds of formula (1)). These new antagonists are useful as NMDA (N-methyl-D-aspartate) antagonists.
Chemical development of MDL 103371: An N-methyl-D-aspartate-type glycine receptor antagonist for the treatment of stroke
Watson, Timothy J.N.,Horgan, Stephen W.,Shah, Ramnik S.,Farr, Robert A.,Schnettler, Richard A.,Nevill Jr., C. Richard,Weiberth, Franz J.,Huber, Edward W.,Baron, Bruce M.,Webster, Mark E.,Mishra, Rajesh K.,Harrison, Boyd L.,Nyce, Phillip L.,Rand, Cynthia L.,Goralski, Christian T.
, p. 477 - 487 (2013/08/07)
MDL 103371 is a N-methyl-D-aspartate (NMDA)-type glycine receptor antagonist for the potential treatment of stroke. Evaluation of five different synthetic routes, which included Stille, Suzuki, enol ether, Knoevenagel, and the Mukaiyama coupling reactions
NMDA (n-methyl-d-aspartate) antagonists
-
, (2008/06/13)
The present invention is new excitatory amino acid antagonists (herein referred to as compounds of formula (1)): below: STR1 These new antagonists are useful as NMDA (N-methyl-D-aspartate) antagonists.
